$8.2 M

Mkt cap, 29-Oct-2019
Aevi Genomic Medicine Net income (FY, 2016)-41.9 M
Aevi Genomic Medicine EBIT (FY, 2016)-41.9 M
Aevi Genomic Medicine Cash, 31-Dec-201639.8 M

Aevi Genomic Medicine Income Statement

Annual

USDFY, 2016

R&D expense

28.6m

General and administrative expense

13.5m

Operating expense total

42.1m

EBIT

(41.9m)

Net Income

(41.9m)

Aevi Genomic Medicine Balance Sheet

Annual

USDFY, 2016

Cash

39.8m

Inventories

335.0k

Current Assets

40.2m

PP&E

377.0k

Total Assets

40.6m

Accounts Payable

137.0k

Current Liabilities

5.6m

Additional Paid-in Capital

215.0m

Retained Earnings

(180.0m)

Total Equity

35.0m

Financial Leverage

1.2 x

Aevi Genomic Medicine Cash Flow

Annual

USDFY, 2016

Net Income

(41.9m)

Depreciation and Amortization

268.0k

Accounts Payable

(1.2m)

Cash From Operating Activities

(32.7m)

Purchases of PP&E

(221.0k)

Cash From Investing Activities

(221.0k)

Cash From Financing Activities

19.7m

Aevi Genomic Medicine Ratios

USDFY, 2016

Financial Leverage

1.2 x